Abiomed (ABMD) 21.84 $ABMD
ABIOMED Shares Down 16.5% Since SmarTrend's Sell Call (ABMD)
Comtex SmarTrend(R) - Fri May 09, 11:10AM CDT
SmarTrend identified a Downtrend for ABIOMED (NASDAQ:ABMD) on March 18th, 2014 at $25.60. In approximately 2 months, ABIOMED has returned 16.55% as of today's recent price of $21.36.
Falling Earnings Estimates Signal Weakness Ahead for ABIOMED (ABMD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:52AM CDT
ABIOMED has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Abiomed Sees Flat Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 9:00AM CDT
For fiscal 2015, Abiomed (ABMD) forecasted revenues between $205 and $212 million for the year.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ABIOMED, Inc.
PR Newswire - Mon May 05, 7:45AM CDT
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ABIOMED, Inc. ("ABIOMED" or the "Company"
(NasdaqGS: ABMD). The investigation focuses on whether the Company and its executives violated federal securities laws.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ABIOMED, Inc. - ABMD
PR Newswire - Thu May 01, 2:28PM CDT
Pomerantz LLP is investigating claims on behalf of investors of ABIOMED, Inc. ("ABMD" or the "Company" (NASDAQ: ABMD) (CUSIP: 003654100). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Abiomed Announces Fourth Quarter Fiscal 2014 Revenue of $50.4 Million, Up 15%
GlobeNewswire - Thu May 01, 6:02AM CDT
-- Record Patient Utilization and 200% Growth in Impella CP Patients
Can ABIOMED (ABMD) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:50PM CDT
ABIOMED (ABMD) has delivered positive surprises in 3 of its last 4 quarters, with an average beat of 73.41%.
ABIOMED Up on License from Opsens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 2:20PM CDT
In a few trading sessions following the announcement, shares of ABIOMED climbed approximately 4.0% to close at $24.95 yesterday.
ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology
GlobeNewswire - Tue Apr 15, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella(R) heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab.
Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free
Abiomed Fourth Quarter Fiscal 2014 Earnings and Conference Call Notification
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
Abiomed Receives CE Mark for Impella RP
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella(R) RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure.
Balanced View on Haemonetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 1:50PM CDT
On Mar 28, we issued an updated research report on Haemonetics Corporation.
Balanced View on Hologic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 1:50PM CDT
On Mar 27, we issued an updated research report on Hologic.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC.
Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ABIOMED's Impella Trial Achieves Enrollment Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:20PM CDT
On reaching the enrollment target, ABIOMED plans to submit the compiled data and seek FDA approval for a Continuous Access Protocol.
ABIOMED Shares Down 16.5% Since SmarTrend's Sell Call (ABMD)
Comtex SmarTrend(R) - Fri May 09, 11:10AM CDT
SmarTrend identified a Downtrend for ABIOMED (NASDAQ:ABMD) on March 18th, 2014 at $25.60. In approximately 2 months, ABIOMED has returned 16.55% as of today's recent price of $21.36.
Falling Earnings Estimates Signal Weakness Ahead for ABIOMED (ABMD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:52AM CDT
ABIOMED has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.
Abiomed Sees Flat Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 9:00AM CDT
For fiscal 2015, Abiomed (ABMD) forecasted revenues between $205 and $212 million for the year.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ABIOMED, Inc.
PR Newswire - Mon May 05, 7:45AM CDT
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ABIOMED, Inc. ("ABIOMED" or the "Company"
(NasdaqGS: ABMD). The investigation focuses on whether the Company and its executives violated federal securities laws. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ABIOMED, Inc. - ABMD
PR Newswire - Thu May 01, 2:28PM CDT
Pomerantz LLP is investigating claims on behalf of investors of ABIOMED, Inc. ("ABMD" or the "Company"
(NASDAQ: ABMD) (CUSIP: 003654100). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. Abiomed Announces Fourth Quarter Fiscal 2014 Revenue of $50.4 Million, Up 15%
GlobeNewswire - Thu May 01, 6:02AM CDT
-- Record Patient Utilization and 200% Growth in Impella CP Patients
Can ABIOMED (ABMD) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:50PM CDT
ABIOMED (ABMD) has delivered positive surprises in 3 of its last 4 quarters, with an average beat of 73.41%.
ABIOMED Up on License from Opsens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 2:20PM CDT
In a few trading sessions following the announcement, shares of ABIOMED climbed approximately 4.0% to close at $24.95 yesterday.
ABIOMED's Impella RP Bags CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:50PM CDT
Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology
GlobeNewswire - Tue Apr 15, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced its acquisition of an exclusive license from collaboration partner Opsens (TSX-V:OPS), a leading developer of fiber optic sensors. Through this exclusive licensing agreement, which covers the use of certain optical sensor technology in the field of cardio-circulatory assist devices, Opsens' miniature optical pressure sensors will be integrated into the Impella(R) heart pump catheters to help further automate the control and operation of the Impella device in the catheterization lab.
Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free
Abiomed Fourth Quarter Fiscal 2014 Earnings and Conference Call Notification
GlobeNewswire - Thu Apr 10, 7:00AM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, May 1, 2014, the Company will release financial results for the fourth quarter of fiscal 2014. The Company will host a conference call to discuss the results on Thursday, May 1, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
Abiomed Receives CE Mark for Impella RP
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received CE Marking approval in the European Union to market the Impella(R) RP device, a new percutaneous Impella heart pump that provides temporary ventricular support for patients with right ventricular failure.
Balanced View on Haemonetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 1:50PM CDT
On Mar 28, we issued an updated research report on Haemonetics Corporation.
Balanced View on Hologic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 1:50PM CDT
On Mar 27, we issued an updated research report on Hologic.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, will be attending and exhibiting at the American College of Cardiology (ACC) annual 2014 scientific sessions, scheduled from March 29 - 31, at the Walter E. Washington Convention Center in Washington, DC.
Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ABIOMED's Impella Trial Achieves Enrollment Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 2:20PM CDT
On reaching the enrollment target, ABIOMED plans to submit the compiled data and seek FDA approval for a Continuous Access Protocol.
